Pharmacological inhibitors of CDK4/6 have become the standard of care in advanced hormone receptor-positive breast cancer [7, 11] and have shown promising results in clinical trials across multiple cancer types [11], including lung cancer [12]. The gene discussed is CDK4; the disease is lung cancer.